Search Result

Results for "

oxygen consumption

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Reactive Oxygen Species (2) Adrenergic Receptor (2) AMPK (1) Apoptosis (4) Bacterial (2) Fatty Acid Synthase (FASN) (1) Fungal (2) Interleukin Related (1) Isotope-Labeled Compounds (1) Mitochondrial Metabolism (4) Na+/K+ ATPase (1) NADPH Oxidase (1) PDK-1 (2) Phosphatase (2) Phosphodiesterase (PDE) (1) Succinate Dehydrogenase (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (1) Infection (4) Inflammation/Immunology (1) Metabolic Disease (6)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Reactive Oxygen Species

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155363

AMPK activator 13	AMPK	Metabolic Disease
AMPK activator 13 is a potent activator of AMPK. AMPK activator 13 inhibits mitotic clonal expansion of 3T3-L1 cells by activating AMPK pathway and enhances cell mitochondrial oxygen consumption rate. AMPK activator 13 can be used in study obesity .

HY-131901

Phenylarsine oxide Oxophenylarsine; PhAsO; Arsenosobenzene	Phosphatase	Others
Phenylarsine oxide (PAO), an inhibitor of endocytosis, inhibits PTPε with an IC₅₀ of 18 μM. Phenylarsine oxide (PAO) inhibits oxygen consumption and decreases cellular ATP content overlap with those used to inhibit protein internalization .

HY-18950

GSK2795039 55+ Cited Publications	NADPH Oxidase Reactive Oxygen Species Apoptosis	Cancer
GSK2795039 is a NADPH oxidase 2 (NOX2) inhibitor with a mean pIC₅₀ of 6 in different cell-free assays. GSK2795039 inhibits reactive oxygen species (ROS) production and NADPH consumption . GSK2795039 reduces apoptosis .

HY-146977

LDHA/PDKs-IN-1	PDK-1	Cancer
LDHA/PDKs-IN-1 (compound 20e) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 0.8 and 0.15 μM, respectively. LDHA/PDKs-IN-1 reduces A549 cell proliferation with an EC₅₀ of 13.2 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-1 has the potential for the research of cancer diseases .

HY-146978

LDHA/PDKs-IN-2	PDK-1	Cancer
LDHA/PDKs-IN-2 (compound 20k) is a potent and dual inhibitor of PDKs and LDHA with IC₅₀s of 1.6 and 0.7 μM, respectively. LDHA/PDKs-IN-2 reduces A549 cell proliferation with an EC₅₀ of 15.7 μM and decreases the lactate formation, and increases oxygen consumption. LDHA/PDKs-IN-2 has the potential for the research of cancer diseases .

HY-W267444

Pentyl 4-hydroxybenzoate Amylparaben	Bacterial	Infection
Pentyl 4-hydroxybenzoate (Amylparaben) is a type of paraben compound commonly used as a preservative, it has antibacterial properties and is related to the inhibition of induced oxygen consumption .

HY-N2953

Borapetoside E	Fatty Acid Synthase (FASN)	Metabolic Disease
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .

HY-170404

KF-52	Phosphatase	Metabolic Disease
KF-52 is a phosphofructokinase-1 (PFK1) inhibitor, with an IC₅₀ of 2.1 μM. KF-52 significantly increases the OCR/ECAR (OCR: oxygen consumption rate; ECAR: extracellular acidification rate) ratio .

HY-B2011

Flutolanil	Fungal Mitochondrial Metabolism Succinate Dehydrogenase	Infection
Flutolanil is a broad-spectrum fungicide. Flutolanil inhibits mycelial oxygen consumption and succinate dehydrogenase in mitochondria Complex II. Flutolanil causes endocrine disruption and reproductive disorders in zebrafish after long-term exposure. Flutolanil can be used to control the fungal pathogens induced plant disease .

HY-170369

SHO1122147	Mitochondrial Metabolism	Metabolic Disease
SHO1122147 (Compound 7m) affects the mitochondrial electron transport chain, exhibits mitochondrial uncoupling activity (EC₅₀=3.6 μM), and increases the oxygen consumption rate (OCR=69%) and promotes cellular respiration. SHO1122147 is orally active, and can be used in reaearch of obesity and metabolic dysfunction-associated steatohepatitis (MASH) .

HY-B2011R

Flutolanil (Standard)	Fungal Mitochondrial Metabolism Succinate Dehydrogenase	Infection
Flutolanil (Standard) is the analytical standard of Flutolanil. This product is intended for research and analytical applications. Flutolanil is a broad-spectrum fungicide. Flutolanil inhibits mycelial oxygen consumption and succinate dehydrogenase in mitochondria Complex II. Flutolanil causes endocrine disruption and reproductive disorders in zebrafish after long-term exposure. Flutolanil can be used to control the fungal pathogens induced plant disease .

HY-161027

DHP-B	Apoptosis	Cancer
DHP-B possesses anti-cancer activity and induces apoptosis. DHP-B covalently binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 interaction, leading to increased mitochondrial permeability and reduced oxygen consumption and energy metabolism in CRC cells. DHP-B can be isolated from the plant Peperomia dindygulensis .

HY-117843

Ppc-1	Mitochondrial Metabolism Interleukin Related Bacterial	Infection Metabolic Disease Inflammation/Immunology
Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen *Porphyromonas gingivalis*. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities .

HY-117181

UK-1745	Phosphodiesterase (PDE) Adrenergic Receptor	Cardiovascular Disease
UK-1745 is a cardiotonic agent with vasodilating and antiarrhythmic properties. It increases intracellular levels of cyclic adenosine monophosphate (cAMP) in cardiomyocytes by inhibiting phosphodiesterase III, thereby enhancing myocardial contractility. Additionally, UK-1745 exhibits β-adrenergic receptor blocking activity, which helps reduce the oxygen consumption of the heart and prevent calcium overload. These characteristics make UK-1745 a promising candidate for research in congestive heart failure .

HY-P10622

SHLP-3	Apoptosis Reactive Oxygen Species	Metabolic Disease Cancer
SHLP-3 is a mitochondrial derived peptide encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-3 increases cell viability and reduces apoptosis in insulinoma NIT-1β cells and human prostate cancer 22Rv1 cells. SHLP-3 increases mitochondrial function and exerts cytoprotective effects by increasing mitochondrial oxygen consumption rate (OCR), cellular ATP and reducing the ability to produce ROS. SHLP-3 can be used in the study of diabetes and cancer .

HY-129236

Hellebrin	Na+/K+ ATPase Apoptosis	Cancer
Hellebrin is a bufadienolide compound extracted from plants that can inhibit tumor cell growth. Hellebrigenin shows potential in overcoming cancer cells' resistance to apoptosis stimuli and has also demonstrated anti-proliferation effects in multidrug-resistant (MDR) cancer cell models. Hellebrin can act on Na+/K+-ATPase to regulate intracellular signaling pathways .

HY-132184S

5,6-Epoxyeicosatrienoic acid-d11 5,6-EET-d₁₁; (±)5,6-EpETrE-d₁₁	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .

Cat. No.	Product Name	Target	Research Area

HY-P10622

SHLP-3	Apoptosis Reactive Oxygen Species	Metabolic Disease Cancer
SHLP-3 is a mitochondrial derived peptide encoded by the 16S ribosomal RNA (MT-RNR2) gene. SHLP-3 increases cell viability and reduces apoptosis in insulinoma NIT-1β cells and human prostate cancer 22Rv1 cells. SHLP-3 increases mitochondrial function and exerts cytoprotective effects by increasing mitochondrial oxygen consumption rate (OCR), cellular ATP and reducing the ability to produce ROS. SHLP-3 can be used in the study of diabetes and cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2953

Borapetoside E	Structural Classification Natural Products Source classification Plants Menispermaceae Tinospora crispa (L.) Hook. f. et Thoms	Fatty Acid Synthase (FASN)
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .

Cat. No.	Product Name	Chemical Structure

HY-132184S

5,6-Epoxyeicosatrienoic acid-d11
5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .

5,6-Epoxyeicosatrienoic acid-d11

5,6-Epoxyeicosatrienoic acid-d₁₁ (5,6-EET-d₁₁) is deuterium labeled 5,6-Epoxyeicosatrienoic acid. 5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC₅₀=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks